Cloud Paweletz
Overview
Explore the profile of Cloud Paweletz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr R, et al.
Nat Genet
. 2015 Aug;
47(10):1212-9.
PMID: 26301495
Detection of minor, genetically distinct subpopulations within tumors is a key challenge in cancer genomics. Here we report STAR-FISH (specific-to-allele PCR-FISH), a novel method for the combined detection of single-nucleotide...
12.
Tolaney S, Tan S, Guo H, Barry W, Van Allen E, Wagle N, et al.
Invest New Drugs
. 2015 Jul;
33(5):1108-14.
PMID: 26123926
Background: MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent...
13.
Castellanos-Rizaldos E, Paweletz C, Song C, Oxnard G, Mamon H, Janne P, et al.
J Mol Diagn
. 2015 Mar;
17(3):284-92.
PMID: 25772705
The use of droplet digital PCR (ddPCR) for low-level DNA mutation detection in cancer, prenatal diagnosis, and infectious diseases is growing rapidly. However, although ddPCR has been implemented successfully for...
14.
Janne P, Ou S, Kim D, Oxnard G, Martins R, Kris M, et al.
Lancet Oncol
. 2014 Dec;
15(13):1433-1441.
PMID: 25456362
Background: Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib. However, resistance inevitably develops,...
15.
Nagashima K, Shumway S, Sathyanarayanan S, Chen A, Dolinski B, Xu Y, et al.
J Biol Chem
. 2010 Dec;
286(8):6433-48.
PMID: 21118801
Phosphoinositide-dependent kinase 1 (PDK1) is a critical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable interest as an oncology drug target. Despite progress characterizing PDK1 as...
16.
Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al.
BMC Med Genomics
. 2010 Jul;
3:26.
PMID: 20591134
Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway...
17.
Kubota K, Anjum R, Yu Y, Kunz R, Andersen J, Kraus M, et al.
Nat Biotechnol
. 2009 Oct;
27(10):933-40.
PMID: 19801977
Constitutive activation of one or more kinase signaling pathways is a hallmark of many cancers. Here we extend the previously described mass spectrometry-based KAYAK approach by monitoring kinase activities from...
18.
Pollard H, Eidelman O, Jozwik C, Huang W, Srivastava M, Ji X, et al.
Mol Cell Proteomics
. 2006 Jul;
5(9):1628-37.
PMID: 16829594
In previous studies with cystic fibrosis (CF) IB3-1 lung epithelial cells in culture, we identified 194 unique high abundance proteins by conventional two-dimensional gel electrophoresis and mass spectrometry (Pollard, H....
19.
Szemes M, Gyorgy A, Paweletz C, Dobi A, Agoston D
Neurochem Res
. 2006 Apr;
31(2):237-46.
PMID: 16604441
AT-rich DNA elements play an important role in regulating cell-specific gene expression. One of the AT-rich DNA binding proteins, SATB1 is a novel type of transcription factor that regulates gene...
20.
Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin P, et al.
Mol Genet Metab
. 2006 Jan;
87(4):303-10.
PMID: 16406648
Antibody microarrays are a new proteomic technology, which we have developed as a platform for identifying a cystic fibrosis (CF)-specific serum proteomic signature. Serum samples from CF patients have been...